Publications by authors named "Timothy Perren"

Claim this Profile
A
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study.
Ailsa J Oswald, Stefan N Symeonides, Duncan Wheatley, Stephen Chan, Adrian Murray Brunt, Timothy Perren

Breast Cancer Res Treat· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.
Benoit You, Lilian Van Wagensveld, Michel Tod, Gabe S Sonke, Hugo M Horlings, Timothy Perren

Br J Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer.
Vladislav Berdunov, Steve Millen, Andrew Paramore, Peter Hall, Timothy Perren

J Med Econ· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological response.
William Stevens, Isabelle M Farrow, Leonidas Georgiou, Andrew M Hanby, Timothy J Perren

Br J Radiol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.
Sarah P Blagden, Adrian D Cook, Christopher Poole, Lesley Howells, Ian A McNeish, Timothy Perren

Lancet Oncol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7).
Olivier Colomban, Michel Tod, Julien Peron, Timothy J Perren, Alexandra Leary

JNCI Cancer Spectr· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study.
Marcia Hall, Gianfilippo Bertelli, Louise Li, Clare Green, Steve Chan, Timothy J Perren

Int J Gynecol Cancer· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
Peter Schmid, Jacinta Abraham, Stephen Chan, Duncan Wheatley, Adrian Murray Brunt, Timothy Perren

J Clin Oncol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.
Robert L Hollis, Michael Churchman, Caroline O Michie, Tzyvia Rye, Laura Knight, Timothy Perren

Cancer· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Martin Gore, Allan Hackshaw, William E Brady, Richard T Penson, Richard Zaino, Timothy Perren

Gynecol Oncol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A functional form for a representative individual arterial input function measured from a population using high temporal resolution DCE MRI.
Leonidas Georgiou, Daniel J Wilson, Nisha Sharma, Timothy J Perren, David L Buckley

Magn Reson Med· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.
Antonio González Martín, Amit M Oza, Andrew C Embleton, Jacobus Pfisterer, Jonathan A Ledermann, Timothy J Perren

Gynecol Oncol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical impact of using complex molecular profiling strategies in routine oncology practice.
Jean-François Laes, Philippe Aftimos, Philippe Barthelemy, Joaquim Bellmunt, Guy Berchem, Timothy J Perren

Oncotarget· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.
Stefan Kommoss, Boris Winterhoff, Ann L Oberg, Gottfried E Konecny, Chen Wang, Timothy Perren

Clin Cancer Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study.
Michael Wallington, Emma B Saxon, Martine Bomb, Rebecca Smittenaar, Matthew Wickenden, Timothy Perren

Lancet Oncol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial.
Sebastian Hinde, David Epstein, Adrian Cook, Andrew Embleton, Timothy Perren

Value Health· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Jonathan A Ledermann, Andrew C Embleton, Fharat Raja, Timothy J Perren, Gordon C Jayson

Lancet· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discordance between the results and conclusions of ICON7 - Authors' reply.
Amit M Oza, Adrian D Cook, Richard Kaplan, Mahesh K B Parmar, Timothy J Perren

Lancet Oncol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Amit M Oza, Adrian D Cook, Jacobus Pfisterer, Andrew Embleton, Jonathan A Ledermann, Timothy J Perren

Lancet Oncol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.
Sean Kehoe, Jane Hook, Matthew Nankivell, Gordon C Jayson, Henry Kitchener, Timothy Perren

Lancet· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents.
Fiona J Collinson, Jenny Seligmann, Timothy J Perren

Curr Oncol Rep· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mucinous tumours of the ovary.
Jay D Naik, Jenny Seligmann, Timothy J Perren

J Clin Pathol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.
David Miles, Henri Roché, Miguel Martin, Timothy J Perren, David A Cameron

Oncologist· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine

N Engl J Med· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma.
Naveen S Vasudev, Ioannis Trigonis, David A Cairns, Geoff D Hall, David P Jackson, Timothy J Perren

Arch Gynecol Obstet· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis